Analysts' recommendations: PExA AB

11-07	Pexa - Q3 Presentation 2025	FW
11-07	Pexa Reports Minor Earnings Changes as Company Advances Toward Diagnostic Applications	FW

More recommendations

Managers and Directors: PExA AB

Manager	Title	Age	Since
Bengt Tomas Jan Gustafsson CEO	Chief Executive Officer	55	-
Jörgen Östling CTO	Chief Tech/Sci/R&D Officer	-	31/12/2017
Svante Höjer CTO	Chief Tech/Sci/R&D Officer	65	31/12/2014

Director	Title	Age	Since
Anna-Carin Olin BRD	Director/Board Member	66	31/12/2009
Claes Frederik Holmberg CHM	Chairman	72	30/01/2014
Björn Lennart Dahlöf BRD	Director/Board Member	73	31/12/2020

More insiders

Medical Diagnostic & Testing Equipment

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PEXA AB	-1.97%	-16.29%	-	-	5.36M
SARTORIUS AG	+0.26%	+1.73%	+27.75%	-36.95%	16.48B
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	-7.73%	-4.31%	-1.62%	+97.57%	1.83B
QUIDELORTHO CORPORATION	-6.72%	-1.09%	-31.08%	-80.48%	1.19B
ECKERT & ZIEGLER SE	-0.22%	-1.52%	-35.29%	+22.23%	985M
CONTEC MEDICAL SYSTEMS CO.,LTD	+0.18%	+1.92%	-42.95%	-52.01%	661M
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.	-0.89%	+0.60%	-47.04%	-52.44%	536M
VAREX IMAGING CORPORATION	-1.13%	+11.87%	+76.01%	-46.01%	522M
REVENIO GROUP OYJ	+0.94%	+1.89%	-49.23%	-46.12%	393M
CELLAVISION AB	-0.27%	-3.15%	-14.57%	-28.25%	373M
Average	-1.75%	+1.17%	-13.12%	-24.72%	2.55B
Weighted average by Cap.	-0.82%	+1.12%	+14.97%	-27.00%

See all sector performances

PExA AB is a Sweden-based company engaged in the advanced equipment and technology industry. The Company develops, manufactures and markets a non-invasive research instrument to study respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The instrument provides lung researchers with a non-invasive method for collecting microscopic particles, potential biomarkers for diseases, from small airways in exhaled air to diagnose, monitor and provide treatment of respiratory diseases.

Employees

Sector

Advanced Medical Equipment & Technology

Calendar

08-28 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change
06/08/26	€0.0298	-1.97%
05/08/26	€0.0304	-0.65%
04/08/26	€0.0306	-1.92%
03/08/26	€0.0312	-5.45%
31/07/26	€0.0330	-5.17%

Delayed Quote Deutsche Boerse AG

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Deutsche Boerse AG Other stock markets 14:25:01 06/08/2026 BST			5-day change	1st Jan Change
0.0298 ^EUR	-1.97%		-16.29%	+98.67%

07-28	Pexa's rights issue was oversubscribed	FW
07-13	Pexa - Interview with CEO Tomas Gustafsson	FW

Market Cap	27.06M 2.85M 2.47M 2.32M 2.12M 3.99M 271M 4.05M 10.61M 136M 10.68M 10.45M 455M	P/E 2023	-2.18x	P/E 2024	-1.13x
Enterprise Value	21.47M 2.26M 1.96M 1.84M 1.68M 3.16M 215M 3.21M 8.42M 108M 8.48M 8.29M 361M	EV / Sales 2023	3.92x	EV / Sales 2024	8.49x
Free-Float	-	Yield 2023 *	-	Yield 2024	-

07-28	Pexa's rights issue was oversubscribed	FW
07-13	Pexa - Interview with CEO Tomas Gustafsson	FW
07-10	Pexa raises SEK10m in a directed share issue, Anders Hallberg becomes a major shareholder	FW
07-01	Pexa raises nearly 10 million kronor in fully guaranteed rights issue	FW
06-23	Pexa signs a SEK 7.5m contract with a global pharmaceutical company	FW
06-10	Pexa secures order from the US	FW
06-02	Doctoral thesis presents findings from studies using Pexa technology	FW
05-22	PExA AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-22	Pexa reports revenue growth in Q1 as bottom line improves	FW
05-13	Pexa joins Dutch research project for lung diseases as industrial partner	FW
05-06	PExA AB Auditor Raises 'Going Concern' Doubt	CI
05-04	Pexa secures order from German BAuA	FW
04-20	Additional funding for Örebro University strengthens Pexa's role in research environment	FW

06-23	PExA : signs agreement with global pharmaceutical company for 10 instruments for clinical multicenter study in pulmonary fibrosis, with a value of approximately SEK 7.5 million	PU
06-10	PExA : U.S. government agency customer orders upgrade of existing PExA system	PU
06-02	PExA : New doctoral thesis strengthens PExA’s opportunities in lung cancer and other lung diseases	PU
05-13	PExA : partner in Dutch precision medicine project within COPD and interstitial lung diseases	PU
05-04	PExA : receives order from German Federal Institute BAuA for second instrument	PU

PExA AB Share Price Deutsche Boerse AG

Stocks

FA0

SE0007412374

Advanced Medical Equipment & Technology

Valuation: PExA AB

Chart: PExA AB

Latest news : PExA AB

Analysts' recommendations: PExA AB

Press Releases: PExA AB

Quotes and Performance

Course Extremes

Managers and Directors: PExA AB

Medical Diagnostic & Testing Equipment

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	-1.97%
1 week	-16.29%
Current month	-9.70%
1 month	+11.19%
3 months	+56.84%
6 months	+75.29%
Current year	+98.67%

1 week	0.03	0.03
1 month	0.03	0.04
Current year	0.01	0.05
1 year	0.01	0.05
3 years	0.01	0.05
5 years	0.01	0.05
10 years	0.01	0.05

	2023	2024
Net sales	2.02M 212K 184K 172K 158K 297K 20.16M 302K 790K 10.1M 796K 778K 33.85M	720K 75.7K 65.68K 61.59K 56.27K 106K 7.2M 108K 282K 3.61M 284K 278K 12.09M
Net income	-8.04M -846K -734K -688K -629K -1.19M -80.46M -1.2M -3.15M -40.33M -3.18M -3.11M -135M	-10.16M -1.07M -928K -870K -795K -1.5M -102M -1.52M -3.99M -50.95M -4.01M -3.93M -171M
Net Debt	-9.6M -1.01M -876K -822K -751K -1.42M -96.03M -1.44M -3.77M -48.13M -3.79M -3.71M -161M	-5.59M -588K -511K -479K -437K -825K -55.95M -837K -2.19M -28.04M -2.21M -2.16M -93.96M